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The tremendous clinical and etiological variability between individuals with autism 
spectrum disorder (ASD) has made precision medicine the most promising treatment 
approach. It aims to combine new pathophysiologically based treatments with objective 
tests (stratification biomarkers) to predict which treatment may be beneficial for a particular 
person. Here we discuss significant advances and current challenges for this approach: 
rare monogenic forms of ASD have provided a major breakthrough for the identification 
of treatment targets by providing a means to trace causal links from a gene to specific 
molecular alterations and biological pathways. To estimate whether treatment targets 
thus identified may be useful for larger patient groups we need a better understanding 
of whether different etiologies (i.e., genetic and environmental risk factors acting at 
different critical time points) lead to convergent or divergent molecular mechanisms, 
and how they map onto differences in circuit-level brain and cognitive development, and 
behavioral symptom profiles. Several recently failed clinical trials with syndromic forms 
of ASD provide valuable insights into conceptual and methodological issues linked to 
limitations in the translatability from animal models to humans, placebo effects, and a 
need for mechanistically plausible, objective outcome measures. To identify stratification 
biomarkers that enrich participant selection in clinical trials, large-scale multi-modal 
longitudinal observational studies are underway. Addressing these different factors in the 
next generation of research studies requires a translatable developmental perspective 
and multidisciplinary, collaborative efforts, with a commitment to sharing protocols and 
data, to increase transparency and reproducibility.
Keywords: autism spectrum disorder, biomarkers, precision medicine
iNtrODUctiON
When parents first receive a diagnosis of autism spectrum disorder (ASD) of their child, some of 
their most pressing questions are: what is the prognosis of my child? What has caused his/her autism? 
And what are the treatment options?
Autism spectrum disorder is a clinically and etiologically heterogeneous condition, currently 
estimated to affect between 1 and 1.5% of children and adults worldwide (1, 2). Diagnostic 
ascertainment is based on the behavioral symptom profile alone; the co-occurrence of 
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social-communicative deficits, repetitive and restricted behav-
iors and interests, and sensory processing anomalies [DSM-5 
(3)]. In addition, up to 70% of individuals have one or more 
psychiatric and/or medical comorbidities, such as intellectual 
disability, ADHD, irritability, aggression, anxiety, depression, 
epilepsy, and sleep anomalies (4).
The prognosis is very variable. A recent large-scale longitudi-
nal study showed distinct developmental trajectories in children 
between the ages of 2 and 14 years (5). Children whose symptoms 
were least severe at first diagnosis showed the most symptom 
improvement. However, a subgroup of around 10% of children 
who presented with the most severe social deficits at age 3 years 
made significant gains in their social trajectory across childhood. 
Nevertheless, for the majority of people with ASD, outcome in 
adulthood has been estimated to be “poor” (46%) or even “very 
poor” (12%) (6). IQ and language level are widely considered the 
best predictors of outcome. Beyond this, it is currently largely 
unknown whether different developmental trajectories may 
reflect different biological subgroups, and why some individuals 
develop comorbidities but others do not.
To date, no effective medical treatments are available that 
significantly improve the core symptoms of ASD. Only two 
medications (the second-generation antipsychotics risperidone 
and aripiprazole) have been approved in ASD by the US Food 
and Drugs Administration (FDA) and one (risperidone) by the 
European Medicines Agency (EMA). Both medications are not 
specific for ASD and target associated symptoms, such as aggres-
sion or irritability. Instead, the management of ASD relies heav-
ily on behavioral and educational interventions (7). Although 
several of these programs report significant improvements, 
difficulties in generalizing skills to “real-world” settings, and 
access to these treatments and their expense, remain common 
limitations (8).
tHe cALL FOr A PrecisiON 
MeDiciNe APPrOAcH
Recognition of the phenotypic and etiological variability 
between individuals on the autism spectrum and the lack of 
effective treatments has called for a precision medicine approach. 
This approach aims to identify targeted treatments based on 
the understanding of the underlying pathophysiology and to 
then combine the drug (or intervention) with a companion 
diagnostic (stratification biomarker) to select or exclude patients 
for a particular treatment. Below we review current progress 
and discuss some of the challenges and requirements that still 
lie ahead.
Perhaps the biggest breakthrough for drug discovery in ASD 
came from the identification of syndromic and monogenic 
forms of ASD (where the disorder is thought to be caused by 
a highly penetrant single gene). Hundreds of ASD risk genes 
have been identified (9, 10), and more are expected to be 
found over the next years through whole-genome sequencing 
and studies with larger sample sizes. The significance of these 
discoveries lies in their potential ability to identify a causal link 
from a gene to cellular and molecular mechanisms underlying 
ASD symptoms (11). Moreover, although each of these mono-
genic forms is rare (i.e., found in less than 1% of individuals 
with ASD) different genes have been shown to converge on 
affecting a much smaller number of common pathways (12). 
This finding is crucial as it means that a particular biological 
pathway could be a treatment target rather than individual gene 
products. Treatments thus identified may therefore, potentially, 
be applicable for broader patient groups. Many of these risk 
genes modulate pathways involved in synapse formation and 
function, as well as other cellular functions, such as chromatin 
remodeling and transcription, protein synthesis and degrada-
tion, and receptor signaling (10). Any of these mutations may 
therefore alter essential developmental processes in  utero or 
shortly after birth (13). For example, abnormalities in synapse 
development, function, and plasticity may broadly impact the 
balance between excitation (mainly modulated by glutamate) 
and inhibition (mainly modulated by gamma-aminobutyric 
acid, GABA) In particular, it has been suggested that (some 
forms of) ASD may be linked to disproportionally high levels 
of excitation and cortical network function (14).
Animal models of syndromic and monogenic forms showed 
significant pre-clinical promise such that several molecular aber-
rations and behavioral phenotypes could be reversed through 
pharamacological treatment or genetic rescue – sometimes even 
in adulthood (15, 16). Subsequent Phase I clinical trials using 
mGluR antagonists, or a GABAB agonist, also reported promising 
results.
However, well-powered (Phase IIb or Phase III) double-blind 
placebo-controlled clinical trials with individuals with Fragile X 
syndrome so far produced disappointing results (17). For exam-
ple, two clinical trials, led by Roche and Novartis, respectively, 
reported a lack of efficacy of their mGluR-inhibiting drugs 
(RG7090 and mavoglurant) in Fragile X syndrome. Similarly, 
a trial with arbaclofen, led by Seaside Therapeutics, failed to 
find significant improvements in individuals with Fragile X and 
idiopathic autism relative to placebo. This highlights several 
factors.
First, even monogenic or syndromic forms also involve 
considerably heterogeneous symptom expression. For example, 
although a SHANK3 haploinsufficiency (thought to cause Phelan 
McDermid Syndrome) is one of most penetrant genetic risk 
factors for ASD [approximately 70% (18)], it can also lead to 
ADHD, schizophrenia, or bipolar disorder in a smaller number of 
individuals (19). About 30% of people with Fragile X syndrome 
have ASD (20). Others present with ADHD, anxiety and avoid-
ance behavior, mood instability, or aggressive behavior (21). This 
variable expressivity appears to be not solely explained by the 
size or location of the deletion alone. What are the factors that 
may influence shared vs. distinct developmental outcomes; and 
at what level(s) can divergence or variability be observed?
FActOrs tHAt iMPAct 
DeveLOPMeNtAL OUtcOMe
Figure  1 outlines the interplay between four factors that may 
impact on developmental outcome.
FiGUre 1 | rare and common genetic variants, as well as environmental risk factors (e.g., toxins, maternal infection) acting at different time points 
impact on the developmental outcome. For example, the same rare genetic mutation can either lead to ASD, ASD + ADHD, or ADHD, depending on the 
person’s genomic background (the sum of common variants). Or the effect of a genetic variant could be modulated by environmental insults that occur during the 
first, second or third trimester of the pregnancy. Many ASD risk genes are involved in essential developmental processes including proliferation, neuronal growth and 
differentiation, and synapse formation. These genes are expressed at different times in brain development.
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common variants and Genomic 
Background
The impact of rare mutations on phenotypic outcome may depend 
on genomic background (the sum of common variants). It may 
act as a “buffer” that diminishes or increases the deleterious effect 
of rare variants (CNVs) – for example, by modulating synaptic 
homeostasis (10). For an individual with a genetic background 
that contains a high load of common ASD risk variants, a small 
burden of rare risk genes may suffice to cause ASD. By contrast, 
an individual whose genetic background only includes a small 
number of common risk variants may require a higher burden of 
deleterious mutations to cause ASD. The rare genetic mutation 
may still have some penetrance, but the effect may be “milder,” 
including sub-threshold clinical symptoms (10).
environmental risk Factors
In addition to genetic factors, it is likely that environmental 
influences – notably those acting during the embryonic stage – 
modulate risk for ASD. This includes maternal infections and 
prenatal exposure to teratogenic agents such as valproate acid, 
exposure to toxins, and dysfunction of the immune system (22). 
For instance, human studies comparing monozygotic and dizy-
gotic twins have consistently revealed significant environmental 
influences that account for approximately 5–6% (23) of the 
observed variance in ASD. Moreover, higher concordance rates 
of ASD and other neurodevelopmental disorders in dizygotic 
twins than (singleton) siblings suggest a specific role of the fetal 
environment because both the twins and singletons share 50% 
of their genes (24).
critical Periods
The time when different factors impact on neuronal develop-
ment likely plays a crucial factor in determining developmental 
outcome. Brain development is initially determined by distinct 
temporal and spatial stages of gene expression (25) and intrinsic 
neuronal activity (26) but then becomes actively refined by 
interactions with the environment. Timing could be influenced 
either by genetic factors as different genes are expressed at differ-
ent times in brain development [e.g., in humans genes involved 
in cell proliferation are expressed earlier than those involved in 
synaptogenesis or myelination (25)] or the time when an environ-
mental insult occurs.
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By altering the developmental window during which 
genetic/environmental insults are applied, animal studies can 
trace these effects across cellular, molecular, brain systems, and 
behavioral levels. However, the vast majority of animal studies 
have only tested adult animals. Therefore, we only know the end 
state – and not how abnormalities developed or changed across 
development. To understand this is vital because it is possible 
that some treatment effects may be different in developing vs. 
adult brains. A treatment that is likely only effective in early 
development would raise important ethical implications for 
clinical trial designs that usually first test safety, efficacy and 
side-effects in adults.
trANsLAtABiLitY
One potential factor in failed clinical trials could be limited 
translatability from animal models to humans. Patient-derived 
induced pluripotent stem cells (iPSCs) are an interesting new 
approach that overcomes inter-species differences, although 
the technology is still in need of further development. Recently, 
protocols have been developed to derive iPSCs from peripheral 
blood mononuclear cells (27) or hair roots (28). This makes 
sample collection significantly easier and more viable for vulner-
able and larger patient groups than earlier protocols based on 
fibroplasts (derived from skin biopsies). In addition, the ability 
to freeze keratinocytes themselves now offers great flexibility 
in generating lines from patients with particular genetics and 
phenotypic characteristics. For example, by comparing lines 
from patients with a particular monogenic defect (e.g., with 
SHANK3), but different clinical symptoms we may be able to 
account for differences in genomic background (which is dif-
ficult in animal models) and identify which cellular alterations 
may be linked to the gene vs. particular phenotypic differences. 
Comparison of phenotypes between cells derived from  patients 
with monogenic vs. “idiopathic” forms of ASD provides valuable 
information on how generalizable cellular or molecular altera-
tions identified from specific genetic/environmental processes 
may be for wider patient groups. Currently, the iPSC methodol-
ogy is very costly. However, by studying cell lines of patients 
that are also comprehensively characterized in terms of their 
systems level (MRI, EEG, and PET) and neurocognitive profile 
we will be able to advance our understanding of the relationship 
between cellular, morphological and molecular, and higher level 
phenotypes in the same person. New systems level features of 
brain anatomy, function, and connectivity are now developed 
that offer higher resolution and greater translatability to brain 
phenotypes studied in animal models (29).
We NeeD tO BriDGe LeveLs OF 
ANALYses – cOGNitiON As A 
BLAcK BOX
One of the current challenges for neurobiological hypotheses, 
such as the E/I imbalance hypothesis, lies in its broadness: both 
glutamate and GABA are ubiquitous in the brain. Is the E/I imbal-
ance in ASD cell and/or circuit-specific? Or might phenotypic 
differences linked to E/I imbalances across disorders (e.g., ASD 
vs. schizophrenia, ID) depend on a critical period during which 
they occur? And how do E/I imbalances give rise to characteristic 
cognitive profiles of ASD that involves both weaknesses and 
strengths?
The immature brain undergoes progressive alterations in 
molecular composition and in synchronized currents that 
underpin the development of functional neuronal circuits. 
Synchronized patterns of neuronal activity engage many 
neurons of developing networks, possibly because of efficient 
feed-forward GABA-ergic inhibition. These immature signals 
stop at critical time points to enable behaviorally relevant brain 
activity to emerge, which requires sparse fired, time-locked 
oscillations. Whereas early perturbations during basic circuit 
refinement may lead to widespread abnormalities, later occur-
ring ones may produce more specific and localized disruptions. 
Brain networks may also differ in their resilience to gene dosage 
such that the functional effects of abnormal gene dosage could 
be localized even if the genetic abnormalities are widespread 
(30). Brain networks involved in evolutionarily older biological 
processes are thought to have developed more compensatory 
mechanisms than those supporting more recent cognitive func-
tions. For example, the timing of insults in synapse development 
differentially affects different cortical regions as the timeline 
for synaptogenesis is different across the cortex (31). Changes 
in synaptic function and timing might then particularly disrupt 
the connectivity of higher order association areas, including 
frontal–parietal, frontal–temporal, and frontal–striatal circuits 
(32). This coincides with brain systems supporting higher level 
social-cognitive function or language development, which spike 
in synaptogenesis and plasticity between 1 and 3 years of age (31); 
roughly the time when social and language-related symptoms 
often become first apparent in ASD. Transcriptomics studies of 
co-expression patterns showed enrichment of ASD genes in cor-
tical projection neurons (33), including glutamatergic projection 
neurons in superficial cortical layers (34).
Recently, some efforts were also made in linking glutamate or 
GABA neurotransmission to sensory processing abnormalities. 
For example, deficits in binocular rivalry (35) as well as paradoxi-
cal motion perception (36) in ASD are taken as indirect proxies 
for reduced GABA-ergic signaling. However, this approach makes 
the strong assumption that anomalies in circuits underpinning 
sensory anomalies are “primary deficits” in autism (37, 38) with 
down-stream effects on networks supporting higher level (and 
later developing) cognitive and social-cognitive functions – a 
premise that remains to be further tested.
Finally, some brain circuits may be more affected than others 
because glutamate and GABA modulate and are modulated by 
other neurotransmitter systems in particular brain regions and 
that are crucial for cognitive functions. For example, at birth, 
GABA-ergic signaling shifts from excitation to inhibition due 
to a reduction in intracellular chloride concentration, which in 
turn is mediated by endogenous oxytocin release. This shift in 
GABA-ergic polarity is abolished in mouse models of fragile X 
syndrome and rodents treated with valproate in utero; and some 
evidence indicates that “immature” excitatory GABA-ergic 
activity may persist in people with ASD (39). This provides a 
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potential link of GABA to a cascade effect of social-motivational 
abnormalities that are thought to be modulated by oxytocin.
Well-validated translated cognitive 
tests for Large-scale investigations
Cognitive measures that map onto specific circuits are needed to 
bridge our understanding between systems level and behavioral 
anomalies. For many commonly used tests, psychometric prop-
erties (e.g., test–retest reliability), age norms, are not available. 
We need to invest in well-validated cognitive batteries that are 
equally suitable and meaningful for both children and adults, or 
for which different comparable versions exist. As most syndro-
mic and monogenic forms of ASD involve varying degrees of 
intellectual disability, these tests should also be sensitive across 
the ability ranges, including profound intellectual disability 
levels to understand whether mechanisms are shared or different 
between these forms of ASD.
WHAt Are MecHANisticALLY 
PLAUsiBLe cLiNicAL eNDPOiNts?
International regulators, such as the FDA, require clinical trials 
to select only one assessment as the primary endpoint against 
which the success of a study is measured. Currently, the lack of a 
truly mechanistic understanding of the link between molecular, 
neuroanatomical/functional, and cognitive processes impedes 
informed selection of “primary endpoints.” For example, in 
a pilot trial of insulin-like growth factor-1 (IGF-1) in Phelan 
McDermid Syndrome the Aberrant Behavior Checklist (ABC) 
social withdrawal subscale was chosen as the primary outcome 
measure because it is well validated in ASD and ID and accepted 
within pediatric psychopharmacology research (40). In the 
STX209 arbaclofen trial with volunteers with “idiopathic” ASD, 
the ABC-irritability subscale was used as the primary outcome 
measure; again because the measure is known to be sensitive to 
change in pharmacologic trials. However, in both examples there 
was no mechanistic reason why the growth-stimulating hormone 
should primarily affect social symptoms or a specific GABAB 
receptor agonist should “specifically” affect irritability (rather 
than core social deficits of ASD). Also, in some instances, the 
clinical outcome measure (irritability) did not directly translate 
to the most consistent behavioral changes identified in the mouse 
model (learning) (17).
PLAceBO eFFects
Placebo effects are a major difficulty for testing treatment 
efficacy in double-blind randomized control trials, which result 
from participants’ expectation that they are receiving a treat-
ment and may lead to conscious or unconscious behavioral 
changes. Even the support, attention, and interest from the 
research team compared to the person or family’s everyday 
experience may have a “therapeutic” effect. The effect size of the 
placebo response in medication trials for ASD is estimated to 
be “moderate” (41). Recently, trial designs have been proposed 
that aim to address the interaction between those behavioral 
changes and treatment (42). In addition, demonstration of 
target engagement using objective measures may be one way 
forward to evaluate the efficacy of the treatment in clinical tri-
als, even when – by virtue of the placebo effects – changes in 
overall outcome may not be significantly different between the 
treatment and control groups.
strAtiFicAtiON BiOMArKers
The next important step is to select particular patients groups 
for clinical trials that are more likely to respond to the treat-
ment under consideration. Despite an explosion of biomarker 
research over the past years, we currently do not have a single 
validated or clinically useful biomarker for ASD. Biomarkers 
have been defined as “a characteristic that is objectively 
measured and evaluated as an indication of normal biological 
processes, pathogenic processes, or pharmacologic responses to 
a therapeutic intervention” (43). In the past, using case–control 
designs, the majority of research studies focused on the identi-
fication of diagnostic biomarkers to provide a discrete and objec-
tive indication of diagnostic status (i.e., whether or not someone 
has an ASD). Although many studies reported significant mean 
group differences in, for example, performances on a range of 
cognitive tests, or in brain structure, function, or connectivity 
(using MRI methods), inconsistencies in findings and failure 
to replicate are common problems. Moreover, it is important 
to note that a mean group difference alone (especially with 
moderate effect sizes) by no means indicates that that measure 
has diagnostic biomarker utility. This further requires an almost 
complete non-overlap of the distributions of individuals in the 
case and control groups (and, according to traditional categori-
cal classifications, individuals with other neurodevelopmental 
or neuropsychiatric conditions).
Stratification biomarkers divide a group of patients into sub-
groups with shared biological characteristics. These subgroups 
may differ in terms of their clinical symptom profile and/or etiol-
ogy. Stratification markers may be primarily clinically relevant if 
they have either prognostic value, i.e., they assess the (untreated) 
progression and outcome of the disorder, or predictive value, i.e., 
they estimate the probability of response to a given treatment. 
Stratification biomarker research in ASD is still in its infancy. 
Difficulties for stratification research have been primarily studies 
with small sample sizes, such that the majority of cognitive or 
neuroimaging studies include 15–30 participants per group – 
which are associated with limited power, especially if a group 
were divided into two or more subgroups.
Large-scale multi-center multidisciplinary observational 
studies, such as the EU-AIMS Longitudinal European Autism 
Project (LEAP) are currently underway that have sufficient power 
to identify stratification markers (44). Multi-modal assessments 
of each individual allow us to identify genetic, molecular, circuit-
based, and behavioral markers.
One approach to stratification is to split the sample based 
on a  priori participant criteria (e.g., sex, developmental level). 
For example, there is some evidence that females with ASD 
differ from males with ASD in terms of their cognitive profile, 
neuroanatomy, or function (45) and that females may require a 
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higher burden of genetic risk factors to develop ASD [i.e., being 
more protected from developing ASD (46)]. There may also be 
differences between individuals with ASD with/without distinct 
co-occurring conditions, such as ADHD or anxiety. In addi-
tion, unsupervised, data-driven methods may be particularly 
useful to identify subtypes based on differences in, for example, 
brain anatomy, function, and/or cognitive profile. To do this, 
hierarchical clustering methods (47) or normative modeling 
approaches to neuroimaging data (48), have recently been used. 
Larger-scale neuroimaging studies of ASD [e.g., EU-AIMS 
LEAP (44); Province of Ontario Neurodevelopmental Disorders 
Network, POND (49)] or efforts to aggregate neuroimaging data 
from different laboratories [Autism Brain Image Data Exchange, 
ABIDE (50)] now begin to provide cohorts of sufficient sizes and 
to enable replication. In contrast to the relative high costs of MRI 
scans, electrophysiological methods are relatively less expensive, 
and easy to use in young children and even infants, and indi-
viduals with intellectual disabilities (51). Valid EEG stratification 
markers may therefore be in principle more feasible to implement 
in clinical practice. Many circuits underpinning fundamental 
bio-behavioral dimensions affected in ASD (e.g., social cognition, 
reward processing) cut across different neurodevelopmental and 
neuropsychiatric disorders. Therefore, a biomarker that estimates 
deficits in, for example, (neural activation underlying) emotional 
reactivity or reward sensitivity does not necessarily have to be 
specific to ASD but instead may predict dimensional symptom 
severity (52).
Multi-modal biomarkers (e.g., combining resting-state EEG 
and fMRI) likely have improved prognostic as well predictive 
value relative to markers based on one modality. For example, 
abnormalities in gamma band oscillations could indicate either 
increased excitatory (e.g., glutamatergic) or reduced inhibi-
tory (e.g., GABA-ergic) signaling. Additional information on 
glutamate vs. GABA concentrations as derived from MRS or 
behavioral proxies of GABA signaling may help to interpret an 
individual’s score on the EEG measure. For a stratification bio-
marker to be predictive of treatment response those differences 
are critical as it may indicate whether – broadly – a GABA agonist 
or glutamate (receptor) antagonist may be more likely to be effec-
tive for a particular individual. Also a fuller understanding of an 
individual’s cognitive profile across domains, and the relationship 
between cognitive strengths and weaknesses is crucial, as indi-
viduals with ASD and their families may be more likely to accept 
future medical treatments if they could be reassured that those 
strengths, which form an important part of a person’s identity, 
are not blunted by them.
Longitudinal designs with at least three time points are 
needed that concurrently track changes in the clinical, neuro-
cognitive, functional, and anatomical trajectories to ascertain the 
prognostic value of stratification biomarkers. This way, we can 
begin to model whether a person whose social-communicative 
skills improve between, say childhood and adolescence has a 
different neurobiological profile to someone whose symptoms 
stay the same or worsen. Identification of convergent/diver-
gent pathways into the disorder (risk biomarkers) would be 
particularly useful to estimate whether a child will develop an 
ASD before it is clinically manifest and to offer intervention 
or treatments during early development. Research on risk bio-
markers typically employs the high-risk infant sibling design, 
which capitalizes on the finding that siblings of a child with 
ASD have a 20-fold increased risk to also developing ASD. So 
far, the majority of infant-at-risk studies have treated “high-risk” 
infants as a relatively homogeneous group and only typically 
stratified by whether or not they developed ASD at age 2–3 years. 
Identification of “prodromal” subgroups is difficult given that 
this design is so costly and the number of children who develop 
ASD in these cohorts is relatively small.
Validation of stratification biomarker requires determining 
their accuracy (i.e., sensitivity, specificity, positive and negative 
predictive values), plausibility (causal or mechanistically under-
standable), reliability in relating to a certain clinical endpoint, 
and reproducibility across clinically relevant settings (53). To 
increase reproducibility, large-scale consortium studies, such as 
the IMI-funded EU-AIMS (54) and the NIMH funded Autism 
Biomarker Consortium-Clinical Trials, are committed to sharing 
protocols and data.
cONcLUsiON
The current assumption that ASD involves multiple etiologies 
and pathophysiological mechanisms makes precision medi-
cine the most promising approach to effective treatments for 
individuals with the overall umbrella condition. Because in 
the majority of individuals with ASD (including most with IQ 
in the normal range) the etiology is currently not known, the 
approach hinges on a better understanding of whether cellular 
or molecular mechanisms are shared. The recently failed clinical 
trials with monogenic forms of ASD point to further obstacles: 
conceptual and methodological issues linked to translatability 
from animal models to humans, clinical trial design, placebo 
effects, and selection of mechanistically plausible, objective 
outcome measures. Addressing these different factors in the 
next generation of research studies requires a translatable 
developmental perspective and multidisciplinary, collaborative 
initiatives.
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